CCI-779 (Temsirolimus) Exhibits Increased Anti-Tumor Activity in Low EGFR Expressing HNSCC Cell Lines and Is Effective in Cells With Acquired Resistance to Cisplatin or Cetuximab

Journal of Translational Medicine - United Kingdom
doi 10.1186/s12967-015-0456-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Nuclear EGFR Contributes to Acquired Resistance to Cetuximab

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

P1.13-13 Potent Anti-Tumor Effect of Ganetespib in Acquired EGFR-TKI Resistance NSCLC Cells

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Lymphotoxin-Β Interacts With Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel in Vivo Model of Acquired Cetuximab Resistance

Clinical Cancer Research
Cancer ResearchOncology
2011English

Aberrant HER3 Ligand Heregulin-Expressing Head and Neck Squamous Cell Carcinoma Is Resistant to Anti-Egfr Antibody Cetuximab, but Not Second-Generation EGFR-TKI

Oncogenesis
Cancer ResearchMolecular Biology
2019English

Over-Expression of BAG-1 in Head and Neck Squamous Cell Carcinomas (HNSCC) Is Associated With Cisplatin-Resistance

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2017English

FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2010English

Emergence of KRAS Mutations and Acquired Resistance to Anti-Egfr Therapy in Colorectal Cancer

Nature
Multidisciplinary
2012English

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-Egfr Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

JAMA Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy